Evaluation of TRPA1 as a Therapeutic Target in <i>MYCN</i>‐Amplified Neuroblastoma
TRPA1 is expressed in NB tumors, and pharmacological TRPA1 inhibition can be effective in vitro and synergistic when used as pretreatment to chemotherapy. However, the tested inhibitors did not show in vivo efficacy, at least as monotherapy.
Authors
- Adriana Mañas (ORCID: https://orcid.org/0000-0002-6955-1754)
- J. Nilsson
- Alexandra Seger (ORCID: https://orcid.org/0000-0003-3191-5302)
- Daniel Bexell (ORCID: https://orcid.org/0000-0001-9426-9550)
- Isaac Vieco-Martí (ORCID: https://orcid.org/0000-0003-0423-8756)
- Javanshir Esfandyari
- Kristina Aaltonen (ORCID: https://orcid.org/0000-0001-5104-735X)
- Rosa Noguera (ORCID: https://orcid.org/0000-0003-4546-7459)
- Mia Engström
- José Ramón Pascual Franco Martínez
- E. Olmos
- Sofía Granados-Aparici (ORCID: https://orcid.org/0000-0003-4448-3254)
- Samuel Navarro (ORCID: https://orcid.org/0000-0001-5016-5653)
- Dora Adamič
Institutions
- Universitat de València (ES)
- Lund University (SE)
- Hospital Universitario La Paz (ES)
- Spanish National Cancer Research Centre (ES)
- Hospital La Paz Institute for Health Research (ES)
- Centro de Investigación del Cáncer (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1002/pbc.31875
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Kungliga Fysiografiska Sällskapet i Lund
- Barncancerfonden
- Science for Life Laboratory
- Skånes universitetssjukhus